AI & ChatGPT searches , social queriess for CD19
Search references for CD19. Phrases containing CD19
See searches and references containing CD19!
Search references for CD19. Phrases containing CD19
See searches and references containing CD19!CD19
Biomarker for B cell lineage
B-lymphocyte antigen CD19, also known as CD19 molecule (Cluster of Differentiation 19), B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12
CD19
Pharmaceutical drug
tumor cells. Blinatumomab is a bispecific CD19-directed CD3 T-cell engager that specifically targets the CD19 antigen present on B cells. Blinatumomab
Blinatumomab
Genetically engineered T cell
dual targeting of CD19 plus CD22 or CD19 plus CD20 have demonstrated promise, and trials studying bispecific targeting to circumvent CD19 down-regulation
CAR_T_cell
Monoclonal antibody linked to a toxic substance
Anti-CD19 immunotoxin is a monoclonal antibody linked to a toxic substance. It is being studied in the treatment of some types of B-cell cancer. Anti-CD19
Anti-CD19_immunotoxin
Gene therapy medication
medication used for the treatment of acute lymphoblastic leukemia. It is a CD19-directed genetically modified autologous T-cell immunotherapy. The most common
Obecabtagene_autoleucel
Type of cytotoxic lymphocyte
NK cells derived from umbilical cord blood have been used to generate CAR.CD19 NK cells. These cells are capable of self-producing the cytokine IL-15, thereby
Natural_killer_cell
Experimental drug
humanised monoclonal antibody that binds CD19 and Fc gamma receptor IIb to inhibit B cells, plasmablasts, and CD19-expressing plasma cells." Perugino, Cory
Obexelimab
American immunologist
integral to the success of CAR therapies. In 2003, Sadelain's lab identified CD19 as a target for CAR therapy in mice. Following the establishment of clinical
Michel_Sadelain
Type of blood cancer
B-cells based on their expression of B-cell marker proteins (e.g. CD20, CD19, CD22, CD79, PAX5, BOB1, OCT2, an immunoglobulin [usually IgM but occasionally
Diffuse_large_B-cell_lymphoma
Australian biotechnology company
immunity. Solid tumours don't express CD19 on their cell surface, therefore introducing the CF33-CD19 allowed for CD19 to be present on the solid tumour cell
Imugene
Blood cancer characterized by overproduction of lymphoblasts
fragment (scFv) designed to recognize the cell-surface marker CD19 as a method of treating ALL. CD19 is a molecule on all B-cells and can be used to distinguish
Acute_lymphoblastic_leukemia
Monoclonal antibody
monoclonal antibody that binds to and depletes CD19+ B cells including plasmablasts and plasma cells (a CD19-directed cytolytic antibody). The most common
Inebilizumab
White blood cell that secretes large volumes of antibodies
surface antigens, and do not express common pan-B cell markers, such as CD19 and CD20. Instead, plasma cells are identified through flow cytometry by
Plasma_cell
Canadian physician (born 1973)
Type 2 Diabetes Naturally". Clinical Diabetes. 37 (3): 302–303. doi:10.2337/cd19-0025. PMC 6640893. PMID 31371867. Ward, Shaun (2024). "The Diabetes Code:
Jason_Fung
Fragment
Immuntherapie CD19-positiver Leukämien und Lymphome [Development and characterisation of bispecific antibody derivatives for the immunotherapy of CD19-positive
Single-chain variable fragment
Single-chain_variable_fragment
Pharmaceutical drug
designed for the treatment of CD19-positive acute lymphoblastic leukemia and B-cell non-Hodgkin lymphoma. It consists of an anti-CD19 mAb linked to monomethyl
Denintuzumab_mafodotin
Protein found in humans
Complement receptor 2 interacts with CD19, and, on mature B cells, forms a complex with CD81 (TAPA-1). The CR2-CD19-CD81 complex is often called the B cell
Complement_receptor_2
Type of immune cell
Flores-Borja F, Rawlings DJ, Isenberg DA, Ehrenstein MR, Mauri C (January 2010). "CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals
Regulatory_B_cell
Medication to treat large B-cell lymphoma
and neurological toxicities. Due to CD19 being a pan-B cell marker, the T-cells that are engineered to target CD19 receptors on the cancerous B cells also
Axicabtagene_ciloleucel
Genetic abnormality in leukemia cancer cells
the person potentially toxic chemotherapy. Blinatumomab a CD19 monoclonal antibody (with CD19 present on B-lineage ALL cells) may be used in relapsed or
Philadelphia_chromosome
American biotechnology company
modified to express a chimeric antigen receptor designed to target the antigen CD19, a protein expressed on the cell surface of B-cell lymphomas and leukemias
Kite_Pharma
Type of white blood cell
the activity of CD21, a surface receptor in complex with surface proteins CD19 and CD81 (all three are collectively known as the B cell coreceptor complex)
B_cell
Medical therapy involving transplant of cells expanded ex vivo
CD19-targeted T cells with added DNA to stimulate cell division. As of 2015 trials had treated about 350 leukemia and lymphoma patients. Antigen CD19
Adoptive_cell_transfer
Immune disorder
failure in antibody production. Mutations in the genes encoding ICOS, TACI, CD19, CD20, CD21, CD80, and BAFFR have been identified as causative of CVID. Susceptibility
Common variable immunodeficiency
Common_variable_immunodeficiency
Artificial protein
example, AFM11 is based on the TandAbs platform and targets both CD3 and CD19 to achieve therapeutic effects. AFM11 showed dose-dependent inhibition of
Bispecific monoclonal antibody
Bispecific_monoclonal_antibody
Belgian pharmaceutical company
co-develop MacroGenics cancer drug candidate (MGD011) which targets both CD19 and CD3 proteins in treating B-cell malignant tumours. This could net MacroGenics
Janssen_Pharmaceuticals
Medical condition
an abnormal immunophenotype (CD38+ CD56+ CD19−) mixed in with cells of a normal phenotype (CD38+ CD56− CD19+); in MGUS, on average more than 3% of the
Monoclonal gammopathy of undetermined significance
Monoclonal_gammopathy_of_undetermined_significance
Chain reaction of white blood cell activation
induced by certain medications, such as the CD20 antibody rituximab and the CD19 CAR T cell tisagenlecleucel. The experimental drug TGN1412—also known as
Cytokine_release_syndrome
Medical condition
with chimeric antigen receptor (CAR) T cells that recognize CD19+ B cells. This shows that CD19-targeting CAR T cells could be a new therapy for patients
Antisynthetase_syndrome
American biopharmaceutical company
cancer. The trials will assess combinations of MEDI4736 and one of Juno's CD19 directed chimeric antigen receptor T cell candidates. In May 2015, the company
Juno_Therapeutics
Species of spider
1202875 EUNIS: 226548 Fauna Europaea: 351544 Fauna Europaea (new): 6ed96eb2-cd19-4759-b952-08cb817d1258 GBIF: 2140934 iNaturalist: 784200 IRMNG: 10895194
Agroeca_proxima
Medical condition
CLL/SLL, atypical CLL/SLL, and non-CLL/SLL phenotypes. These markers are: CD5, CD19, CD20, CD23, and immunoglobulins (Ig) (either Ig light chains or complete
Monoclonal B-cell lymphocytosis
Monoclonal_B-cell_lymphocytosis
Cancer of plasma cells
surface; myeloma cells are often CD56, CD38, CD138, and CD319 positive and CD19, CD20, and CD45 negative. Flow cytometry is often used to establish the clonal
Multiple_myeloma
White blood cell
marrow. Furthermore, expression levels of surface markers, such as CD38 and CD19, vary among plasma cells and are associated with functional differences.
Long-lived_plasma_cell
Hematological malignancy
or bone marrow. The hairy cells are larger than normal and positive for CD19, CD20, CD22, CD11c, CD25, CD103, and FMC7 antigens. (CD103, CD22, and CD11c
Hairy_cell_leukemia
Gene therapy medication
back to the person. The T cells are engineered to target a protein called CD19 that is common on B cells. A chimeric T cell receptor ("CAR-T") is expressed
Tisagenlecleucel
Subtype of white blood cell
Gamma delta T cells Immunoregulation and cytotoxicity 5% (2–8%) TCRγδ and CD3 B cells Secretion of antibodies 23% (18–47%) MHC class II, CD19 and CD20
Lymphocyte
Natural killer T cells genetically engineered to combat cancer
recruiting other effectors. Preclinical models show CAR-NK efficacy against CD19+ lymphomas and HER2+ breast cancer. Natural killer cells derive from various
CAR-NK
American physician-scientist
CAR T cells targeting CD19. Dr. Kochenderfer and coworkers conducted early studies that demonstrated the effectiveness of anti-CD19 CAR T cells against
James_N._Kochenderfer
Autoimmune disease in which the immune system attacks healthy tissue
Mougiakakos D, Böltz S, Wilhelm A, Aigner M, et al. (October 2022). "Anti-CD19 CAR T cell therapy for refractory systemic lupus erythematosus". Nature Medicine
Lupus
Pharmaceutical drug
of follicular lymphoma. Tafasitamab is a humanized Fc-modified cytolytic CD19 antibody. Tafasitamab may cause serious side effects including infusion related
Tafasitamab
Medication
antibody-drug conjugate (ADC) composed of a humanized antibody targeting the protein CD19. The most common side effects include increased levels of gamma-glutamyltransferase
Loncastuximab_tesirine
Protein found in humans
B cells form complexes with a co-accessory activation complex containing CD19, CD81, and the fragilis/Ifitm (murine equivalents of LEU13) proteins. The
Complement_receptor_1
Endocrine gland
of clusters of differentiation, cell surface proteins – namely CD30, with CD19, CD20 and CD22, and with the absence of CD15. Other markers may also be used
Thymus
— February 7, 2003 Kitt Peak Spacewatch · 2.1 km MPC · JPL 276437 2003 CD19 — February 8, 2003 Socorro LINEAR · 1.4 km MPC · JPL 276438 2003 CG19 —
List of minor planets: 276001–277000
List_of_minor_planets:_276001–277000
Monoclonal antibody
Taplitumomab paptox Monoclonal antibody Type Whole antibody Source Mouse Target CD19 Clinical data ATC code none Identifiers CAS Number 235428-87-2 Y ChemSpider
Taplitumomab_paptox
B cell not yet exposed to an antigen
; Greinix, Hildegard T.; Schlenke, Peter; Steinmetz, Ivo (2021-12-07). "CD19+IgD+CD27- Naïve B Cells as Predictors of Humoral Response to COVID 19 mRNA
Naive_B_cell
American physician and immunologist
humans. Her group was among the first to demonstrate impressive activity of CD19 chimeric antigen receptor (CAR T cells) therapies for childhood leukemia
Crystal_Mackall
receptor to elicit a response from the T cell. Once an antigen binds to the CD19 receptor, immediate downregulation in B-cell receptor (BCR) signal expression
B10_cell
Manipulation of an organism's genome
Davila ML, Riviere I, Park J, Wang X, Cowell LG, et al. (March 2013). "CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory
Genetic_engineering
CD3 5 CD13 4 CD4 4 CD14 4 CD5 5 CD15 4 CD6 4 CD16 4 CD7 7 CD17 5 CD8 4 CD18 5 CD9 6 CD19 7 CD10 4 CD20 6 PLEO 21 At-large 35 Total pledged delegates 161
2000 Illinois Democratic presidential primary
2000_Illinois_Democratic_presidential_primary
Histamine receptor
biosynthesis of interferon gamma in peripheral human blood mononuclear cells and in CD19-depleted cell subsets". Immunology Letters. 70 (2): 95–99. doi:10
Histamine_H1_receptor
Treatment of cancer using drugs that inhibit cell division or kill cells
cell lymphoma. This anti-CD19 CAR-T cell therapy is commonly known to decrease CAR-T cells which bind to the glycoprotein CD19. By decreasing the number
Chemotherapy
Class of artificial monoclonal antibodies
assess their therapeutic efficacy and safety. Blinatumomab links T cells with CD19 receptors found on the surface of B cells. The Food and Drug Administration
T_cell_engager
Human blood group classification
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
Kell_antigen_system
CAR-T therapy
days. Rapcabtagene autoleucel is an autologous CD19-directed CAR-T cell therapy that targets the CD19 antigen expressed on B-cell malignancies. The therapy
Rapcabtagene_autoleucel
Type of white blood cell
CD123, CD49b(DX-5)+, CD69+, Thy-1.2+, 2B4+, CD11bdull, CD117(c-kit)−, CD24−, CD19−, CD80−, CD14−, CD23−, Ly49c−, CD122−, CD11c−, Gr-1−, NK1.1−, B220−, CD3−
Basophil
Mammalian protein found in humans
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
ENTPD1
Acute inflammation diseases of the optic nerve and spinal cord
disorders with rituximab using a maintenance treatment regimen and close CD19 B cell monitoring. A six-year follow-up". Journal of the Neurological Sciences
Neuromyelitis optica spectrum disorder
Neuromyelitis_optica_spectrum_disorder
Mammalian protein found in Homo sapiens
receptor proteins, including the B cell antigen receptor (BCR), CD40, or CD19. The abbreviation Lyn is derived from Lck/Yes novel tyrosine kinase, Lck
LYN
myeloperoxidase, while B and T lymphoid lineages are indicated by the expression of CD19 and cytoplasmic CD3. The fundamental feature of MPAL involves two types of
Mixed-phenotype acute leukemia
Mixed-phenotype_acute_leukemia
Protein(s) forming a major part of an organism's immune system
IV, et al. (July 2015). "Long-Lived Plasma Cells Are Contained within the CD19−CD38hiCD138+ Subset in Human Bone Marrow". Immunity. 43 (1): 132–145. doi:10
Antibody
treatment-resistant CD19-positive B-cell cancers, in which patients' CD4+ and CD8+ T cells are genetically engineered to express a CD19-specific CAR. Preliminary
David_G._Maloney
Protein-coding gene in humans
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
CD79A
This receptor binds to IGHV4-34 on malignant or pathogenic B cells. Unlike CD19-targeted CAR T therapies, which eliminate many healthy B cells and suppress
CART4-34_therapy
Political term
AD49, AD51, AD58, AD62, AD70, AD73, AD76 0 43.9% 28.5% 13.9% 2018 12 CD13, CD19, CD32, AD4, AD7, AD20, AD21, AD27, AD51, AD61, AD64, AD69 0 32.6% 23.6% 11
Write-in_candidate
U.S. House district for California
district RAND California Election Returns: District Definitions California Voter Foundation map - CD19 37°36′N 120°00′W / 37.6°N 120°W / 37.6; -120
California's 19th congressional district
California's_19th_congressional_district
Cell based gene therapy
single-arm multicenter trial that evaluated brexucabtagene autoleucel, a CD19-directed chimeric antigen receptor (CAR) T-cell therapy. Participants received
Brexucabtagene_autoleucel
Protein found in humans
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
ADAM17
Swedish-British pharmaceutical company
these trials involved combinations of MEDI4736 and one of Juno Therapeutics' CD19 directed chimeric antigen receptor T-cell candidates. In June, the company
AstraZeneca
Medical technology
therapy used genetically modified T cells to attack cells that expressed the CD19 protein to fight the disease. In 2013, the researchers announced that 26
Gene_therapy
Gene therapy medication
Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies"
Lisocabtagene_maraleucel
128721272 rs11539209 ZDHHC12 ENSG00000160446 CD19 WEGEPPC[L/V]P DQB1*02:01 chr16 28933075 rs2904880 CD19 ENSG00000177455 LB-PI4K2B-1S SRSS[S/P]AELDRSR
Minor histocompatibility antigen
Minor_histocompatibility_antigen
Protein-coding gene in the species Homo sapiens
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
NKG2D
Gene therapy medication used to treat multiple myeloma
Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies"
Ciltacabtagene_autoleucel
Protein which in humans is encoded by the SDC1 gene
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
Syndecan_1
Medical condition
sometimes IgM): common variable immunodeficiency (CVID), ICOS deficiency, CD19 deficiency, TACI (TNFRSF13B) deficiency, BAFF receptor deficiency. Normal
Humoral_immune_deficiency
Family of glycoproteins
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
CD1
Protein found in humans
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
CD244
Group of proteins
antibody fragments, such as anti-CD19/CD16, allow the targeting of immunotherapeutic drugs to the cancer cell. Anti-CD19/CD16 diabodies have been shown
CD16
Mammalian protein found in Homo sapiens
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
CEACAM6
Swiss pharmaceutical company
Genentech for inflammatory and auto-immune diseases. NI-1701, an anti-CD47, anti-CD19 bispecific antibody in development for treatment of B-cell hematological
Novimmune
Protein-coding gene in humans
Fearon DT (1997). "Membrane IgM-induced tyrosine phosphorylation of CD19 requires a CD19 domain that mediates association with components of the B cell antigen
CD79B
Ability of the immune system to quickly and specifically recognize an antigen
made to kill any type of cell. A heavy-handed approach that targets every CD19, which is found on every B cell, has received much press due its fast and
Immunological_memory
Large protein superfamily of cell surface and soluble proteins
domains and are therefore also members of the IgSF. Co-receptors CD4 CD8 CD19 Co-receptors and accessory molecules: Other molecules on the surfaces of
Immunoglobulin_superfamily
Protein involved in multiple prion diseases
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
Major_prion_protein
Medical condition
lymphoma from other small B-cell NHLs. B-cell-associated antigens such as CD19, CD20, CD22, and CD79a are usually expressed. In contrast to small lymphocytic
MALT_lymphoma
Type of blood cancer
has not yet undergone the germinal center reaction), that is CD5, CD20, CD19 positive with expression of IgM and IgD with monoclonal kappa and gamma light
Mantle_cell_lymphoma
Biological membrane structure
Kirchmeier MJ, Gagne JF (1999). "Cellular trafficking and cytotoxicity of anti-CD19-targeted liposomal doxorubicin in B lymphoma cells". Journal of Liposome
Lipid_bilayer
Mammalian protein found in humans
member 8 (IGSF8, CD316) and CD36. It forms a signal transduction complex with CD19, CD21 and Leu-13 (CD225) on the surface of the B cell. On T cells CD81 associates
CD81
Protein-coding gene in the species Homo sapiens
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
IL18RAP
Protein found in humans
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
CD78
Mammalian protein found in Homo sapiens
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
Nectin-3
Public university in Konya, Turkey
Associate Chief Physician at Meram School of Medicine. Helped to identify CD19 Deficiency Syndrome. Metin Şahin, Assistant professor - European Taekwondo
Selçuk_University
Gene therapy medication
Warning for T cell Malignancies Following Treatment with BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies"
Idecabtagene_vicleucel
Protein-coding gene in the species Homo sapiens
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
KIR3DL2
Protein-coding gene in the species Homo sapiens
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
C-C_chemokine_receptor_type_7
Mammalian protein found in Homo sapiens
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
Integrin_beta_1
Protein found in humans
CD4 CD5 CD6 CD7 CD8 a CD9 CD10 CD11 a b c d CD13 CD14 CD15 CD16 A B CD18 CD19 CD20 CD21 CD22 CD23 CD24 CD25 CD26 CD27 CD28 CD29 CD30 CD31 CD32 A B CD33
Death_receptor_5
Immunotherapy using T cells
increasingly promising due to protein and cell engineering improvements. Anti-CD19 (CD19 is crucial for B cell lineage, which is overexpressed on leukemic B-cells)
Cellular adoptive immunotherapy
Cellular_adoptive_immunotherapy
CD19
CD19
CD19
CD19
Boy/Male
Tamil
Girl/Female
Hindu
Moon light, Black Sky
Girl/Female
Gujarati, Hindu, Indian, Marathi
Eye
Boy/Male
English
Ropemaker.
Boy/Male
Australian, Christian, Danish, Hebrew
Devoted to God; Diminutive of Lemuel
Boy/Male
English
Little shield.
Girl/Female
Spanish
From Dionysus god of wine.
Girl/Female
Welsh
Beautiful and fair.
Female
English
Latin form of Greek Ariadnê, ARIADNE means "utterly pure." In mythology, this is the name of the daughter of King Minos.
Boy/Male
Biblical
That beholds.
CD19
CD19
CD19
CD19
CD19